A Phase 3 interventional study of acetylsalicyclic acid (ASA) and Clopidogrel in Covert Brain Infarction, sponsored by Aarhus University Hospital. Recruiting at 14 sites in 5 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by Aarhus University Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Dementia with a site in Denmark — 6 open to participants now, 12 under way, 1 of them phase 3. Dementia · Denmark.
Among the 30 studies in Dementia with a site in Denmark, this one is the 3rd largest by planned enrollment of the 21 interventional ones that give a count, is one of 6 that started in 2025, is one of 4 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 23rd registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →6 of the 30 studies in Dementia with a site in Denmark are open now. Recruiting first, the newest first:
University of Southern Denmark · Sites in Denmark
Ages 65+
Aarhus University Hospital · Sites in Denmark
Ages 60+
Zealand University Hospital · Sites in Denmark
Ages 50+ · Healthy volunteers
Center for Clinical Research and Prevention · Sites in Denmark
Ages 18+ · Healthy volunteers
University Hospital Bispebjerg and Frederiksberg · Sites in Denmark
Ages 60+ · Healthy volunteers
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 5 · Phase 4 2
First in 2003; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,652 is above the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 339 across the 21 interventional studies, 140 across the 9 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 30 have an industry lead sponsor. The 10 most frequent:
Aarhus University Hospital is the lead sponsor of 298 studies on the registry; 80 are open to participants now.
Aarhus University Hospital has 2 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
3 of the studies in Dementia with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06624267University Hospital Bispebjerg and FrederiksbergTest of Reproducibility of [15O]H20-PET Assessment of Brain Perfusion | 2027-01 |
| NCT06451692University of Southern DenmarkPrioritising Patient Medication Review: Hospitals Reaching Out | 2027-01-01 |
| NCT07741526Arctic TherapeuticsSafety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD) | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Dementia with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Magnetic resonance imaging (MRI) is commonly used in healthcare, and sometimes it shows small areas of brain damage called Covert Brain Infarcts (CBIs). These are usually found by chance when people have scans for things like headaches or dizziness. Although CBIs don't cause symptoms at the time, they are linked to a higher risk of future stroke and death.
There is currently no standard treatment for CBIs, and doctors have different approaches-some give stroke-preventing medication (like antiplatelets or statins), while others don't treat at all. This is mostly because there isn't enough research yet.
This study will test whether stroke-preventing treatments help people with CBIs. It will also look at whether having a CBI increases the risk of dementia, and whether treatment might lower that risk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will initiate treatment with Aspirin or Clopidogrel. The decision on which of the two drugs to initiate is at the discretion of the treating physician/center.
Drug: acetylsalicyclic acid (ASA) · Drug: Clopidogrel
Patients will be treated with high-intensity statin therapy (Atorvastatin 40 mg once daily or Rosuvastatin 20 mg once daily)
Drug: Rosuvastatin · Drug: Atorvastatin
Both types of medication are initiated as described in group A and B
Drug: acetylsalicyclic acid (ASA) · Drug: Clopidogrel · Drug: Rosuvastatin · Drug: Atorvastatin
This group follows the current European recommendations of primary prevention which do not include statins and APT agents. If statins and/or platelet inhibitors are started during the study-period it should adhere to primary prevention guidelines. All four groups receive advice on lifestyle optimization and blood pressure management.
Daily dose 75 mg to 100 mg p.o.
Also known as: Aspirin
Daily dose 75 mg p.o.
Daily dose 20 mg p.o. (10 mg once daily for the first 4 weeks, then 20 mg once daily for the remainder of the study period if tolerated). If Rosuvastatin 20 mg is not tolerated, a dose reduction to 10 mg is allowed.
Daily dose 40 mg p.o. If Atorvastatin 40 mg is not tolerated, a dose reduction to 20 mg is allowed.
Major Adverse Cardiac and Cerebral Events (MACCE) at 12 and 36 months
MACCE are defined as the occurrence of any of the following events * All cause death: Death from any cause * Acute myocardial infarction: Admission with a discharge diagnosis of ST-elevation myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI) and * Stroke: AIS\* or Intracerebral hemorrhage (non-traumatic) \*Including Transient Ischemic Attack (TIA) with evidence of brain tissue infarction i.e. remission of symptoms within 24 hours but who have an acute ischemic lesion on diffusion weighted imaging MRI. All events qualifying for a MACCE event will be adjudicated by the Clinical event committee. Accepted timeframe for evaluation is +/- 30 days
Time frame: 12 months and 36 months post-randomization.
Major and fatal bleeding at 12 and 36 months
Major and fatal bleeding events are defined according to criteria established by the International Society on Thrombosis and Haemostasis (ISTH): * Fatal bleeding, and/or * Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome, and/or * Bleeding leading to a drop in hemoglobin of ≥20 g/L (1.24 mmol/L), or requiring transfusion of two or more units of whole blood or red cells. All qualifying events will be adjudicated by an independent Clinical Event Committee (CEC). The accepted time window for assessment is ±30 days.
Time frame: 12 months and 36 months post-randomization.
All-cause dementia
Dementia is identified through phone contact and review of the patient's electronic health record, based on national diagnostic standards. Accepted diagnoses align with ICD-10 and ICD-11. ICD-10 codes include: dementia in Alzheimer's disease (F00.0-F00.9, DG30.0-DG30.9), vascular dementia (F01.0-F01.9, F00.2), dementia in other diseases classified elsewhere (F02.0-F02.8), unspecified dementia (F03.9), Lewy body dementia (DG31.8E), progressive isolated aphasia (DG31.0A), Pick disease (DG31.0B), and unspecified degenerative disease of the nervous system (DG31.9). ICD-11 codes include: dementia due to Alzheimer's disease (6D80), cerebrovascular disease (6D81), Lewy body disease (6D82), frontotemporal dementia (6D83), other specified diseases (6D85.Y), and dementia of unknown or unspecified cause (6D8Z). The accepted time window for evaluation is ±30 days.
Time frame: 12 months and 36 months post-randomization.
Cardiovascular-related mortality
Information about cardiovascular mortality is collected from telephone contacts and from the patient's electronic health record. See the table below for the definition of cardiovascular mortality. Cardiovascular Mortality are defined as: * Acute MI * Sudden cardiac death * Heart failure * Stroke: death as a direct consequence or complication of stroke * Cardiovascular procedure * Cardiovascular-related haemorrhage: non-stroke intracranial haemorrhage (subdural hematoma), non-procedural or non-traumatic vascular rupture (e.g. aortic aneurysm), or haemorrhage causing cardiac tamponade * Death due to other cardiovascular causes: a cardiovascular death not included in the above categories but with a specific, known cause (e.g., pulmonary embolism or peripheral arterial disease) Accepted time for evaluation is +/- 30 days
Time frame: 12 months and 36 months post-randomization.
Cognitive decline
A significant cognitive decline, defined as a ≥2-point reduction in Montreal Cognitive Assessment (MoCA) scores at 36 months. The participant's score on the full 12 item in-person MoCA (30 points) at the initial visit is compared to the scores on the telephone administrated Tele-MoCA (items from MoCA not requiring the use of a pencil and paper or visual stimulus, maximum of 22 points) after 12 and 36 months. Accepted time for evaluation is +/- 30 days
Time frame: After 12 months and a end of treatment at 36 months
Serious adverse event (SAE)
Information on SAEs will be reported by the investigators and recorded in the eCRF.
Time frame: From enrollment to the end of treatment at 36 months
Baseline MRI risk markers, quantified using the ordinal simplified SVD-score (small vessel disease) score
Simple SVD defined as score: Microbleeds: 0 microbleeds = 0 point; ≥ 1 microbleed = 1 point White matter hyperintensities (Fazekas): Fazekas 0-1 = 0 point; Fazekas 2-3 = 1 point. Lacunes: 0-2 lacunes = 0 point; \>2 lacunes = 1 point. Total SVD score (range): 0-3.
Time frame: After 12 months and at the end of treatment at 36 months
Physical activity levels
Baseline physical activity levels are measured by the International Physical Activity Questionnaire (IPAQ).It yields a categorical score: low, moderate, or high level of physical activity. The follow-up assessment will be performed by staff from the enrolling site. Accepted time for evaluation is +/- 30 days
Time frame: At baseline
Modified Rankin Scale (mRS) score
The change in mRS score will be assessed to evaluate shifts in functional independence and disability over time. The mRS ranges from 0 to 6, with higher scores indicating worse outcomes. The follow-up assessment at 12 and 36 months will be performed by staff from the enrolling site. Accepted time for evaluation is +/- 30 days
Time frame: From baseline to 12 months and to the end of treatment at 36 months
Clinical Frailty Scale (CFS) score
The change in CFS score will be assessed from baseline to 12 and 36 months to evaluate the progression of frailty and its impact on functional status and overall health over time. It ranges from 1 to 9, with 1 indicating "very fit" and 9 indicating "terminally ill." The follow-up assessments at 12 and 36 months will be performed by staff from the enrolling site Accepted time for evaluation is +/- 30 days
Time frame: From baseline to 12 months and to the end of treatment at 36 months
Barthel Index (BI) for Activities of Daily Living (ADL)
The Barthel Index is a score that describes the degree of independence in relation to assistance from another person. It ranges from 0 to 100, with higher scores indicating greater independence. A score close to 100 reflects that the individual is self-sufficient, whereas lower scores indicate increasing dependence on others in daily activities. A score near 0 typically suggests that the individual is bedridden and requires help with all tasks. The follow-up assessments at 12 and 36 months will be performed by staff from the enrolling site. Accepted time for evaluation is +/- 30 days
Time frame: From enrollment to 12 months and to the end of treatment at 36 months
Quality of life (EQ-5D)
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The follow-up assessments at 12 and 36 months will be performed by staff from the enrolling site. Accepted time for evaluation is +/- 30 days
Time frame: From enrollment to 12 months and to the end of treatment at 36 months
CBI subtype
The CBI subtype and infarct appearance will be described by the enrolling physician, who has been trained to identify these findings on MRI. The baseline MRI will be visually graded by the investigators and the total SVD score calculated. The DICOM (Digital Imaging and Communications in Medicine) file containing the MRI will be downloaded and uploaded to the electronic case report form (eCRF) at redcap.au.dk, for later assessment by an imaging core lab.
Time frame: At baseline
MRI-based assessment of small vessel disease progression (sub-study)
At centers participating in the extended imaging sub-study, patients will be invited to a follow-up MRI after 3 years (+/- 1 months). The baseline MRI should be of sufficient quality and with a field strength of 3 Tesla. The follow-up MRI will contain diffusion-weighted imaging, apparent diffusion coefficient, Susceptibility Weighted Imaging (preferred) or T2\* gradient-recalled echo, and T2 fluid-attenuated inverse recovery. Newly developed lacunar and/or cortical infarctions will be recorded and a SVD score will be calculated. If possible T1 weighted sequences will be performed. The MRI will be uploaded to eCRF. The number of CBIs, number of cerebral microbleeds, deep white matter lesions (Fazekas grade), MRI SVD score, and Global Cortical Atrophy (GCA) Scale will be assessed by two blinded assessors. If there is disagreement, a third and final blinded assessor will perform the assessment.
Time frame: After 36 months (+/- 1 months)
MRI-based assessment of white matter lesion (WML) volume growth
WML volume will be estimated using semiautomatic software, such as 3D Slicer (an open-source medical image analysis tool) or a similar alternative. WML will be segmented together with volume quantification. It will be performed by two blinded assessors, and the final volume will represent a consensus volume between the assessors.
Time frame: 36 months (+/- 1 month)
Carotid plaque quantification on ultrasound
At centers participating in the extended imaging sub-study, patients will be invited to an ultrasound examination at the baseline visit. The common- and internal carotid artery will be assessed for signs of atherosclerotic disease and presence, size and morphology of plaques, classifying them based on echogenicity (homogeneous or heterogeneous), surface characteristics (smooth or irregular), and calcification (presence or absence) ipsilateral to the CBI. If bilateral CBIs are present, the left side will be scanned. A plaque score will be calculated based on sum scores for each plaque identified in the carotid and intracranial arteries based on size and morphology. Plaque Grading Consensus will be used and range from no plaque (IMT \< 1.5mm), protuberant/diffuse \< 1.5mm IMT, protuberant/ diffuse with IMT 1.5-2.4mm or protuberant/ diffuse with IMT \>2.5mm.
Time frame: At baseline
Pulsatility index on ultrasound
Pulsatility Index (PI) of the mid- and distal middle cerebral artery (MCA) will be measured using transcranial Doppler ultrasound to assess blood flow resistance within cerebral vessels. It will be calculated based on the difference between peak systolic and end-diastolic blood flow velocities relative to the mean flow velocity: PI=(Peak Systolic Velocity-End-Diastolic Velocity)/Mean Velocity. PI has been associated with increased microvascular resistance, white matter disintegration, plaque burden.
Time frame: At baseline
Plan to share: Yes — Individual participant data underlying the baseline screening visit and 3 years outcome can be shared after de-identification, upon reasonable request and proposals should be directed at the principal study investigator. To gain access to these data, data requestors will need to sign a data processing agreement. Further, anonymized data will be available through public databases such as the Zenodo open data repository (CERN) or other equivalent databases after trial completion.
Supporting information: Study protocol, Statistical analysis plan
Time frame: After publication of the primary endpoint (estimated Sept 30, 2032)
Access criteria: To gain access to these data, data requestors will need to sign a data processing agreement.
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Sep 2031, 70 months after the start.
Of 34 phase 3 interventional studies under Dementia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 70 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aspirin · Clopidogrel · Rosuvastatin · Atorvastatin